Cargando…
A Simple LC-MS/MS Method for the Quantification of PDA-66 in Human Plasma
The treatment of cancer is one of the most important pharmacotherapeutic challenges. To this end, chemotherapy has for some time been complemented by targeted therapies against specific structures. PDA-66, a structural analogue of the inhibitor of serine–threonine kinase glycogen synthase kinase 3β...
Autores principales: | Schwarz, Rico, Seiler, Elisabeth R. D., Sender, Sina, Pews-Davtyan, Anahit, Murua Escobar, Hugo, Zechner, Dietmar, Beller, Matthias, Junghanß, Christian, Hinz, Burkhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840185/ https://www.ncbi.nlm.nih.gov/pubmed/35164239 http://dx.doi.org/10.3390/molecules27030974 |
Ejemplares similares
-
Characterization of the novel indolylmaleimides' PDA-66 and PDA-377 effect on canine lymphoma cells
por: Liu, Wen, et al.
Publicado: (2016) -
Validation of an LC–MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma
por: Schwarz, Rico, et al.
Publicado: (2022) -
The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells
por: Kretzschmar, Christin, et al.
Publicado: (2014) -
PDA Indolylmaleimides Induce Anti-Tumor Effects in Prostate Carcinoma Cell Lines Through Mitotic Death
por: Schille, Jan Torben, et al.
Publicado: (2021) -
Identification of Forced Degradation Products of Itopride by LC-PDA and LC-MS
por: Joshi, Payal, et al.
Publicado: (2011)